SpePharm has completed two pan-European license agreements in 2007 in the field of oncology / supportive care / oral medicine. In 2008, SpePharm has also acquired the Dantrium brands for their commercializations in Europe and certain other markets in the world.
- Dantrium™, Dantrolen IV™ & Dantamacrin™: in its intravenous form, Dantrium is used to treat malignant hyperthermia (a life-threatening reaction to certain gaseous anesthetics) and in its oral form, the control of clinical spastiticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). Acquired from Procter & Gamble Pharmaceuticals (USA).
- Savene® (dexrazoxane hydrochloride) is a systemic antidote against tissue damage due to anthracycline extravasation.
- Xerotin™, artifical saliva for the management of xerostomia (dry mouth); exclusive distribution agreement from Difa Cooper (Italy).
- PROther™ line of products, which contains several forms, are foods for special medical purposes for people with serious protein and/or glutathione deficits.